Castle Biosciences Inc (NAS:CSTL)
$ 24.37 0.63 (2.65%) Market Cap: 672.79 Mil Enterprise Value: 458.63 Mil PE Ratio: 0 PB Ratio: 1.67 GF Score: 79/100

Castle Biosciences Inc at Needham Growth Conference (Virtual) Transcript

Jan 10, 2022 / 05:30PM GMT
Release Date Price: $40.23 (+2.92%)
Mike Matson
Needham & Company - Analyst

Great. Thanks for joining us at the 24th Annual Needham Growth Conference. I am Mike Matson, and I lead the med tech and diagnostics equity research team here at Needham & Company. I am pleased to introduce Castle Biosciences' CEO, Derek Maetzold; CFO, Frank Stokes; and Executive Director, Investor Relations and Communications, Camilla Zuckero. Instead of (technical difficulty), we are going to start out with some slides here, a brief presentation, but we are going to spend most of the time doing a Q&A session. (Conference Instructions)

So with that, I will turn things to Derek, and he will go through a few slides before we get into the Q&A. Derek, if you want to go ahead?

Derek Maetzold
Castle Biosciences, Inc. - President and CEO

Hi, Mike. Thank you for the introduction. Happy new year, everybody. It's good to be here, even if it's over Zoom. I thought I would go through just a couple of slides regarding our year-end results and then, as you said, spend most of the time from a fireside chat

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot